HK1108825A1 - Compositions and methods for treating leukemia - Google Patents

Compositions and methods for treating leukemia

Info

Publication number
HK1108825A1
HK1108825A1 HK07112180.8A HK07112180A HK1108825A1 HK 1108825 A1 HK1108825 A1 HK 1108825A1 HK 07112180 A HK07112180 A HK 07112180A HK 1108825 A1 HK1108825 A1 HK 1108825A1
Authority
HK
Hong Kong
Prior art keywords
methods
compositions
treating leukemia
mammal
leukemia
Prior art date
Application number
HK07112180.8A
Other languages
English (en)
Inventor
Deborah A Thomas
Original Assignee
Talon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Talon Therapeutics Inc filed Critical Talon Therapeutics Inc
Publication of HK1108825A1 publication Critical patent/HK1108825A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK07112180.8A 2004-08-10 2007-11-08 Compositions and methods for treating leukemia HK1108825A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65148204P 2004-08-10 2004-08-10
PCT/US2005/028233 WO2006020618A1 (en) 2004-08-10 2005-08-09 Compositions and methods for treating leukemia

Publications (1)

Publication Number Publication Date
HK1108825A1 true HK1108825A1 (en) 2008-05-23

Family

ID=35414880

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07112180.8A HK1108825A1 (en) 2004-08-10 2007-11-08 Compositions and methods for treating leukemia

Country Status (12)

Country Link
US (2) US20090028933A1 (de)
EP (1) EP1781255B1 (de)
JP (1) JP5199666B2 (de)
AT (1) ATE545408T1 (de)
AU (1) AU2005272946B2 (de)
CA (1) CA2576222C (de)
CY (1) CY1112736T1 (de)
DK (1) DK1781255T3 (de)
ES (1) ES2382337T3 (de)
HK (1) HK1108825A1 (de)
PT (1) PT1781255E (de)
WO (1) WO2006020618A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6723338B1 (en) * 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
WO2011041914A1 (en) * 2009-10-09 2011-04-14 University Health Network (Uhn) Use of flubendazole and vinca alkaloids for treatment of hematological diseases
RU2013129777A (ru) * 2010-12-08 2015-01-20 Ф. Хоффманн-Ля Рош Аг Липосомальный препарат далцетрапиба
RU2655964C2 (ru) 2012-11-20 2018-05-30 Спектрум Фармасьютикалз, Инк. Улучшенный способ получения инкапсулированного в липосомы винкристина для терапевтического применения
KR20160079823A (ko) 2013-11-27 2016-07-06 온코에틱스 게엠베하 티에노트리아졸로디아제핀 화합물을 함유하는 제약 제제를 사용하여 백혈병을 치료하는 방법
WO2015168621A1 (en) * 2014-05-02 2015-11-05 Oncoethix Sa Method of treating acute myeloid leukemia and/or acute lymphoblastic leukemia using thienotriazolodiazepine compounds
EA201791819A1 (ru) * 2015-02-12 2017-12-29 Сиэтл Дженетикс, Инк. Комбинированная терапия с применением конъюгата антитела против cd19 с лекарственным средством и винкристина
US10278979B2 (en) 2015-03-11 2019-05-07 Riken Therapeutic agent for intractable leukemia
TWI678213B (zh) 2015-07-22 2019-12-01 美商史倍壯製藥公司 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物
CN111658636B (zh) * 2020-06-12 2021-04-13 桂林医学院 穿心莲内酯与地塞米松联用在制备复方抗急性淋巴细胞白血病药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4906476A (en) * 1988-12-14 1990-03-06 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs in lungs
US7311924B2 (en) * 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
US6723338B1 (en) * 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
DK1169021T3 (da) * 1999-04-01 2010-01-11 Hana Biosciences Inc Sammensætninger og fremgangsmåder til behandling af lymfom

Also Published As

Publication number Publication date
EP1781255B1 (de) 2012-02-15
JP5199666B2 (ja) 2013-05-15
CY1112736T1 (el) 2016-02-10
JP2008509911A (ja) 2008-04-03
ATE545408T1 (de) 2012-03-15
AU2005272946B2 (en) 2012-01-12
US20120164211A1 (en) 2012-06-28
CA2576222A1 (en) 2006-02-23
ES2382337T3 (es) 2012-06-07
DK1781255T3 (da) 2012-05-29
US20090028933A1 (en) 2009-01-29
WO2006020618A1 (en) 2006-02-23
CA2576222C (en) 2014-09-30
AU2005272946A1 (en) 2006-02-23
PT1781255E (pt) 2012-05-21
WO2006020618A8 (en) 2006-11-02
EP1781255A1 (de) 2007-05-09

Similar Documents

Publication Publication Date Title
HK1108825A1 (en) Compositions and methods for treating leukemia
RS20070029A (en) Compositions for delivering highly water soluble drugs
BE2013C064I2 (de)
WO2005110477A3 (en) Combination therapies for cancer and proliferative angiopathies
IL175714A0 (en) Quinazolinone compounds as anticancer agents
PT1742644E (pt) Composição terapêutica que contém pelo menos um derivado de pirrolobenzodiazepina e fludarabina
WO2004087075A3 (en) Compositions and methods for treating cancer
WO2005084296A3 (en) Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogernase 3
SG160412A1 (en) Anti-igfr1 antibody therapeutic combinations
WO2005070930A3 (en) Tetrahydrocarboline compounds as anticancer agents
TW200621240A (en) Cancer treatments
WO2005094376A3 (en) Synergistic methods and compositions for treating cancer
WO2004030627A3 (en) Synergistic methods and compositions for treating cancer
WO2004006859A3 (en) Platinum compound
PL1781296T3 (pl) Pochodne chinazolinowe i ich zastosowanie w leczeniu nadpłytkowości
HK1121936A1 (en) Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
NZ577393A (en) Use of 3-alpha-androstanediol, optionally in combination with a pde5 inhibitor, in the treatment of sexual dysfunction
SG155939A1 (en) Phosphoindoles as hiv inhibitors
UA83022C2 (uk) Аплідин для комбінованої терапії лейкозу та лімфоми
MXPA05011213A (es) Combinacion de un inhibidor de ciclooxigenasa-2 y un agente antineoplasico tipo alquilacion para tratamiento de neoplasia.
WO2006002088A3 (en) Amino-quinazoline derivatives as antitumor agents
WO2005053725A3 (en) Cancer treatment
WO2005056754A3 (en) Compositions and methods to reduce mutagenesis
WO2006102611A3 (en) Therapeutic agents for the treatment of leukemia
WO2005117545A3 (en) Nitric oxide dioxygenase inhibitors

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20220809